ClinicalTrials.gg
RecruitingNCT02873468Updated Feb 24, 2023

Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis

A Phase 2 interventional study of Florence 30 μg/mL and Florence 60 μg/mL in Eosinophilic Esophagitis, sponsored by EMS. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by EMS · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of three doses of Florence oral suspension on changes of eosinophilic infiltration in esophageal biopsies.

02

Conditions studied

  • Eosinophilic Esophagitis
03

In context

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

This study's planned enrollment of 116 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.

Browse Eosinophilic Esophagitis studies →

Lead sponsor

EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent;
  • Participants aged 18 years or more;
  • Participants diagnosed with eosinophilic esophagitis, defined as:

    1. Presence of symptoms of esophageal dysfunction intermittently or continuously during previous week to the screening visit;
    2. Eosinophilic esophageal inflammation with ≥ 15 eosinophils/high-power field, in the screening endoscopy;
    3. Exclusion of other causes of esophageal eosinophilia.

Exclusion criteria

Exclusion Criteria:

  • Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
  • Participants with a stricture on endoscopy that prevents passage of the endoscope;
  • History of alcohol abuse or drug use;
  • Use of concomitant therapies for any reason that may affect the assessment;
  • History of gastroesophageal surgery;
  • History of the abnormal gastrointestinal disorder;
  • Another disorder that causes esophageal eosinophilia;
  • Pregnancy or risk of pregnancy and lactating patients;
  • Participants with known allergy, or to the components of the medicine used in the clinical trial;
  • Participation in clinical trial in the year prior to this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Florence 30

    Drug: Florence 30 μg/mL

  • Experimental
    Florence 60

    Drug: Florence 60 μg/mL

  • Experimental
    Florence 90

    Drug: Florence 90 μg/mL

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugFlorence 30 μg/mL

    10 mL, oral, twice a day.

    Also known as: EMS oral suspension

  • DrugFlorence 60 μg/mL

    10 mL, oral, twice a day.

    Also known as: EMS oral suspension

  • DrugFlorence 90 μg/mL

    10 mL, oral, twice a day.

    Also known as: EMS oral suspension

  • OtherPlacebo

    10 mL, oral, twice a day.

    Also known as: Florence placebo

06

What researchers measure

Primary outcomes

  1. Proportion of participants presenting a histological response, defined as the presence of ≤ 6 eosinophils/high-power field, at the end of treatment.

    Time frame: 100 days

Secondary outcomes

  1. Incidence and severity of adverse events recorded during the study.

    Time frame: 170 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jul 2025, 51 months after the start.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Aug 19, 2016
StartActual
Apr 19, 2021
Primary completionEst.
Jul 2025
CompletionEst.
Nov 2025
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02873468
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Aug 19, 2016
Start date
Apr 19, 2021
Primary completion
Jul 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Feb 24, 2023

Study contacts

Arthur M Kummer, MD
Contact
pesquisa.clinica@ems.com.br
+551938879851

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion